The article is intended for educational and informational purposes only and should not replace professional medical advice, diagnosis, or treatment.
10.1161/01.HYP.17.5.693
204 Mazdutide, a dual GLP-1/glucagon RA, and retatrutide, a triple GLP-1/GIP/glucagon RA, also have both shown significant weight loss effects in Phase 2 trials
Eric Goldstein, a gastroenterologist in New York City, told Insider that while digestive issues are known side effects of this class of drugs, called GLP-1 receptor agonists, how widespread and severe they are is likely overblown on social media
Not only does it demonstrates beneficial effects in regard to cardiovascular risk factors (ie, diabetes, lipid management, and weight control), but it also has been shown in animal studies to have positive cardiac effects irrespective of its effects on glucose control and weight loss